Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 April 2021 | Story André Damons | Photo Supplied
Keabetswe Modise is graduating cum laude with a Bachelor of Administration Honours degree during the UFS virtual graduation on 19 April.

After repeating Grade 11 three times, a student in the Faculty of Economic and Management Sciences at the University of the Free State (UFS) is graduating cum laude with a Bachelor of Administration Honours degree in April.

Keabetswe Modise, who is graduating on 19 April during the UFS virtual graduation, says she used her earlier failures as motivation to work even harder. 

“I am extremely proud of myself. I chose to win instead of crying over spilled milk. As a black, capable, and independent woman, I told myself that if there is a chance for trauma or depression, there is definitely a chance to succeed and enjoy life. This implies that I can achieve anything that I set my mind to. I now hold my family’s name high in both our community and within our external family,” says a proud Modise.

Modise, a part-time lecturer at the Central University of Technology (CUT) in Welkom, has been accepted to study a Master of Public Policy and Development degree in Japan. Her academic year will commence early in 2022 and will take two years to complete.   

Motivation

“This (academic success) came as a surprise. I never thought that one day I would hold a postgraduate qualification, let alone that such a qualification exists. In high school, I repeated Grade 11 three times. At that time, I was known as the dumbest kid in school and in the community. 

“I was depressed, but I did not know what was going on with me. Therefore, I just wanted to pass my matric and work to survive. During my matric year, I really became more motivated after career orientation. This is when I knew I wanted to experience university life. I also wanted to use the chance to escape the dumb girl concept and come back with a victory to claim back my name. Today I am the most influential girl in my community.”

Making the most of the lockdown

Modise used the COVID-19 pandemic and the lockdown to her advantage, as it gave her the opportunity to not only study online, but to also start a successful fast-food business. 

“The consequences of the pandemic on universities have been to my advantage. I managed to work at home, with limited financial expenses such as transport and printing of documents. Also, my assessments were online. This also gave me the chance to start a fast-food business while tackling academic activities on time. 

“Most importantly, I did not have money for registration, and when the policy changed for late registration due to COVID-19 regulations, it gave me time to make a plan to finance my studies. Fortunately, by August, I received a bursary from the Postgraduate School at the UFS, because the HOD was impressed with my academic record. As much as the effects of COVID-19 were devastating on the lives of people, I managed to achieve my goal,” says Modise. 

Her inspiration 

According to Modise, her parents – who separated when she was very young – inspire her. Says Modise: “I appreciate everything they have done for me. I just want my father to one day address me as Dr Modise, while he and my mother can look back and be proud of the woman I have become.” 

“In this case, I can say that I get inspired by the vision of being applauded by both my mother and father.  Most importantly, I get inspired by the changing philosophy of government management. I admire the impact of globalisation around the world. Today, any academic institution can operate online.” 

Modise’s message to others is that nothing comes easy or without a cost: “It looks like it is impossible, but actually, this is your life. I can motivate someone as much as I can, but if you are not willing to be motivated, nothing can change for you. Also, no one owes anyone anything. This is your journey, drive it.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept